Faculty Opinions recommendation of Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718020296.793478787 ◽

2013 ◽

Author(s):

Arthur Kim

Keyword(s):

Hepatitis C ◽

Phase 2 ◽

Hepatitis C Infection ◽

Multicentre Phase ◽

Phase 2 Trial ◽

Treatment Naïve ◽

Peginterferon Alfa ◽

Download Full-text

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

10.1016/s0140-6736(10)60934-8 ◽

2010 ◽

Vol 376 (9742) ◽

pp. 705-716 ◽

Author(s):

Paul Y Kwo ◽

Eric J Lawitz ◽

Jonathan McCone ◽

Eugene R Schiff ◽

John M Vierling ◽

...

Keyword(s):

Hepatitis C ◽

Phase 2 ◽

Hepatitis C Infection ◽

Multicentre Phase ◽

Phase 2 Trial ◽

Treatment Naïve ◽

Peginterferon Alfa ◽

Download Full-text

Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial

10.1016/s0140-6736(13)60247-0 ◽

2013 ◽

Vol 381 (9883) ◽

pp. 2100-2107 ◽

Author(s):

Kris V Kowdley ◽

Eric Lawitz ◽

Israel Crespo ◽

Tarek Hassanein ◽

Mitchell N Davis ◽

...

Keyword(s):

Hepatitis C ◽

Pegylated Interferon ◽

Interferon Alfa ◽

Phase 2 ◽

Multicentre Phase ◽

Phase 2 Trial ◽

Treatment Naïve ◽

Pegylated Interferon Alfa

Download Full-text

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial

The Lancet Infectious Diseases ◽

10.1016/s1473-3099(13)70033-1 ◽

2013 ◽

Vol 13 (5) ◽

pp. 401-408 ◽

Author(s):

Eric Lawitz ◽

Jay P Lalezari ◽

Tarek Hassanein ◽

Kris V Kowdley ◽

Fred F Poordad ◽

...

Keyword(s):

Hepatitis C ◽

Phase 2 ◽

Hepatitis C Infection ◽

Double Blind ◽

Phase 2 Trial ◽

Treatment Naïve ◽

Peginterferon Alfa

Download Full-text

Faculty Opinions recommendation of Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726172820.793515335 ◽

2016 ◽

Author(s):

Philip Rosenthal

Keyword(s):

Hepatitis C Virus ◽

Liver Disease ◽

Hepatitis C ◽

Virus Infection ◽

Phase 2 ◽

Hepatitis C Virus Infection ◽

Advanced Liver Disease ◽

Download Full-text

Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial

10.1016/s0140-6736(14)61795-5 ◽

2015 ◽

Vol 385 (9973) ◽

pp. 1075-1086 ◽

Author(s):

Eric Lawitz ◽

Edward Gane ◽

Brian Pearlman ◽

Edward Tam ◽

Wayne Ghesquiere ◽

...

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Phase 2 ◽

Efficacy And Safety ◽

Virus Genotype ◽

Phase 2 Trial ◽

Open Label Phase ◽

Download Full-text

Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial

10.1016/s0140-6736(14)61793-1 ◽

2015 ◽

Vol 385 (9973) ◽

pp. 1087-1097 ◽

Author(s):

Mark Sulkowski ◽

Christophe Hezode ◽

Jan Gerstoft ◽

John M Vierling ◽

Josep Mallolas ◽

...

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Phase 2 ◽

Efficacy And Safety ◽

Virus Genotype ◽

Phase 2 Trial ◽

Open Label Phase

Download Full-text

1163 A PHASE 2A STUDY OF BMS-791325, AN NS5B POLYMERASE INHIBITOR, WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C INFECTION

Journal of Hepatology ◽

10.1016/s0168-8278(12)61175-1 ◽

2012 ◽

Vol 56 ◽

pp. S460 ◽

Author(s):

H. Tatum ◽

P. Thuluvath ◽

E. Lawitz ◽

C.T. Martorell ◽

M. Demicco ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Hepatitis C Infection ◽

Ns5b Polymerase Inhibitor ◽

Treatment Naïve ◽

Polymerase Inhibitor ◽

Peginterferon Alfa ◽

Ns5b Polymerase

Download Full-text

Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial

The Lancet Infectious Diseases ◽

10.1016/s1473-3099(16)00052-9 ◽

2016 ◽

Vol 16 (6) ◽

pp. 685-697 ◽

Author(s):

Michael Manns ◽

Didier Samuel ◽

Edward J Gane ◽

David Mutimer ◽

Geoff McCaughan ◽

...

Keyword(s):

Hepatitis C Virus ◽

Liver Disease ◽

Hepatitis C ◽

Virus Infection ◽

Phase 2 ◽

Hepatitis C Virus Infection ◽

Advanced Liver Disease ◽

Download Full-text

1096 ASUNAPREVIR (ASV; BMS-650032), AN NS3 PROTEASE INHIBITOR, IN COMBINATION WITH PEGINTERFERON AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C INFECTION

Journal of Hepatology ◽

10.1016/s0168-8278(12)61108-8 ◽

2012 ◽

Vol 56 ◽

pp. S431-S432 ◽

Author(s):

J.-P. Bronowicki ◽

S. Pol ◽

P. Thuluvath ◽

D. Larrey ◽

C.T. Martorell ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C ◽

Protease Inhibitor ◽

Chronic Hepatitis C ◽

Hepatitis C Infection ◽

Treatment Naïve ◽

Peginterferon And Ribavirin ◽

Download Full-text

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial

10.1016/s0140-6736(13)62121-2 ◽

2014 ◽

Vol 383 (9916) ◽

pp. 515-523 ◽

Author(s):

Eric Lawitz ◽

Fred F Poordad ◽

Phillip S Pang ◽

Robert H Hyland ◽

Xiao Ding ◽

...

Keyword(s):

Phase 2 ◽

Hepatitis C Virus Infection ◽

Phase 2 Trial ◽

Treatment Naïve ◽

Previously Treated Patients ◽

Dose Combination ◽

Previously Treated

Download Full-text